NAIO

Software as a service (SaaS) for medical research and development; Software as a service (SaaS) for clinical trials; Software as a service (SaaS) for medical diagnostic decision making; Software as a service (SaaS) for medical prognostic decision making; Software as a service (SaaS) for treatment predictive decision making; Software as a service (SaaS) for monitoring the status of a medical condition; Software as a service (SaaS) for monitoring the safety of a therapeutic; Software as a service (SaaS) for evaluating the efficacy of a therapeutic; Software as a service (SaaS) for evaluating a pharmacodynamic biomarker; Software as a service (SaaS) for evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Software as a service (SaaS) for evaluating the risk of developing a disorder of the central nervous system; Software as a service (SaaS) for prevention of disorders of the central nervous system; Software as a service (SaaS) for processing, managing, displaying and transmitting images of the central nervous system; Software as a service (SaaS) for dissemination of results or analyses related to any of the above; Cloud computing featuring software for scientific computing for use in the fields of medical research and development; Cloud computing featuring software for scientific computing for use in the fields of clinical trials; Cloud computing featuring software for scientific computing for use in the fields of medical diagnostic decision making; Cloud computing featuring software for scientific computing for use in the fields of medical prognostic decision making; Cloud computing featuring software for scientific computing for use in the fields of treatment predictive decision making; Cloud computing featuring software for scientific computing for use in the fields of monitoring the status of a medical condition; Cloud computing featuring software for scientific computing for use in the fields of monitoring the safety of a therapeutic; Cloud computing featuring software for scientific computing for use in the fields of evaluating the efficacy of a therapeutic; Cloud computing featuring software for scientific computing for use in the fields of evaluating a pharmacodynamic biomarker; Cloud computing featuring software for scientific computing for use in the fields of evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Cloud computing featuring software for scientific computing for use in the fields of evaluating the risk of developing a disorder of the central nervous system; Cloud computing featuring software for scientific computing for use in the fields of prevention of disorders of the central nervous system; Cloud computing featuring software for scientific computing for use in the fields of processing, managing, displaying and transmitting images of the central nervous system; Cloud computing featuring software for scientific computing for disseminating results or analyses related to any of the above; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of medical research and development; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of clinical trials; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of medical diagnostic decision making; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of medical prognostic decision making; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of medical treatment predictive decision making; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of monitoring the status of a medical condition; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of monitoring the safety of a therapeutic; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of evaluating the efficacy of a therapeutic; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of evaluating a pharmacodynamic biomarker; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of evaluating the risk of developing a disorder of the central nervous system; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of prevention of disorders of the central nervous system; Software-as-a-medical-device for medical research and development; Software-as-a-medical-device for clinical trials; Software-as-a-medical-device for medical diagnostic decision making; Software-as-a-medical-device for medical prognostic decision making; Software-as-a-medical-device for treatment predictive decision making; Software-as-a-medical-device for monitoring the status of a medical condition; Software-as-a-medical-device for monitoring the safety of a therapeutic; Software-as-a-medical-device for evaluating the efficacy of a therapeutic; Software-as-a-medical-device for evaluating a pharmacodynamic biomarker; Software-as-a-medical-device for evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Software-as-a-medical-device for evaluating the risk of developing a disorder of the central nervous system; Software-as-a-medical-device for prevention of disorders of the central nervous system

Companion diagnostic for medical research and development; Companion diagnostic for clinical trials; Companion diagnostic for medical diagnostic decision making; Companion diagnostic for medical prognostic decision making; Companion diagnostic for treatment predictive decision making; Companion diagnostic for monitoring the status of a medical condition; Companion diagnostic for monitoring the safety of a therapeutic; Companion diagnostic for evaluating the efficacy of a therapeutic; Companion diagnostic for evaluating a pharmacodynamic biomarker; Companion diagnostic for evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Companion diagnostic for evaluating the risk of developing a disorder of the central nervous system; Companion diagnostic for prevention of disorders of the central nervous system; Consulting services for others in the field of design, planning, and implementation project management of medical research and development; Consulting services for others in the field of design, planning, and implementation project management of clinical trials; Consulting services for others in the field of design, planning, and implementation project management of medical diagnostic decision making; Consulting services for others in the field of design, planning, and implementation project management of medical prognostic decision making; Consulting services for others in the field of design, planning, and implementation project management of treatment predictive decision making;Consulting services for others in the field of design, planning, and implementation project management of monitoring the status of a medical condition; Consulting services for others in the field of design, planning, and implementation project management of monitoring the safety of a therapeutic; Consulting services for others in the field of design, planning, and implementation project management of evaluating the efficacy of a therapeutic; Consulting services for others in the field of design, planning, and implementation project management of evaluating a pharmacodynamic biomarker; Consulting services for others in the field of design, planning, and implementation project management of evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Consulting services for others in the field of design, planning, and implementation project management of evaluating the risk of developing a disorder of the central nervous system; Consulting services for others in the field of design, planning, and implementation project management of prevention of disorders of the central nervous system; Medical analysis services for others in the field of clinical trials; Medical analysis services for others in the field of medical diagnostic decision making; Medical analysis services for others in the field of medical prognostic decision making; Medical analysis services for others in the field of treatment predictive decision making; Medical analysis services for others in the field of monitoring the status of a medical condition; Medical analysis services for others in the field of monitoring the safety of a therapeutic; Medical analysis services for others in the field of evaluating the efficacy of a therapeutic; Medical analysis services for others in the field of evaluating a pharmacodynamic biomarker; Medical analysis services for others in the field of evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Medical analysis services for others in the field of evaluating the risk of developing a disorder of the central nervous system; Medical analysis services for others in the field of prevention of disorders of the central nervous system; Medical analysis services for others in the field of medical research and development; Research and development in the field of biotechnology with a focus on disorders of the central nervous system